@TIDALSupport Hey @TIDAL, please add an option to keep Shuffle ON by default for playlists/My Tracks, especially on Android Auto. It always starts with the same songs unless I manually activate shuffle again.
🚨ULTIMA HORA🚨
SciHub acaba de liberar SciBot una inteligencia artificial que hace referencia a articulos de paga de forma gratuita y te deja descargarlos para revisarlos sin pagar un centavo.
Recuerda NO utilizar estas paginas, sigue pagando en vez de tener acceso gratuito.
IgA nephropathy is the most common cause of immune-mediated glomerular disease worldwide.
📌 This Review summarizes the pathophysiology, epidemiology, clinical presentation, diagnosis, treatment, and prognosis of primary IgA nephropathy in adults.
https://t.co/9KNkN8Cxsl
KDIGO is excited to share the publication of the 2025 Clinical Practice Guideline for the Management of IgA Nephropathy (#IgAN) and IgA Vasculitis (#IgAV), along with the Executive Summary in @Kidney_Int.
Read the Guideline in KI: https://t.co/OvxwTGjjXx
Download the Executive Summary: https://t.co/WLJLwFnlZq
Read the News Release: https://t.co/gHZ1yvcuoe
Co-chaired by Dr. Jürgen Floege (DE) and @BradRovin, this update to the 2021 KDIGO Glomerular Diseases Guideline on IgAN incorporates evidence through August 2024. Given the rapid pace of discovery, KDIGO will continue to update the guideline regularly so clinicians and patients have access to the latest science and recommendations.
“This guideline represents a fundamental shift in how we approach IgA nephropathy,” said Dr. Floege. “For the first time, we can target both the immune mechanisms driving IgA injury and the kidney’s maladaptive responses. This dual strategy offers a roadmap to slow progression and extend kidney survival in ways not possible just a few years ago.”
“The science is moving faster than ever, and the treatment landscape has changed dramatically,” said Dr. Rovin. “With therapies like targeted-release budesonide, sparsentan, and SGLT2 inhibitors, we can intervene earlier and tailor care. We are moving from a single approach to a toolkit of therapies that can truly change outcomes for people around the world."
Download the Guideline: https://t.co/NUzPHXN4Zu
¿Te has preguntado cuánto gana un médico especialista en distintas partes del mundo?
Te presento un análisis en dólares anuales 💵🇺🇸 para que compares realidades entre Suiza, USA, Dinamarca, Alemania, España, UK, Colombia, Argentina, Egipto, Congo y México. 👇
Cardiovascular–kidney–metabolic (CKM) syndrome incorporates the interplay between #MetabolicSyndrome, obesity, diabetes mellitus, and kidney and cardiovascular disease, and a treatment algorithm has been developed.
https://t.co/gq0SkzFBn4
Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease:
a clinical practice document by the European Renal Best Practice board of the European Renal Association
🔓https://t.co/aeRulmvdqM